Protein C occupies a uniquely important position in the biology of blood. Synthesised in the liver as an inactive zymogen, it circulates until the thrombin-thrombomodulin complex on endothelial cells cleaves it into activated protein C, or APC. Once activated, APC performs a remarkable triple duty: it proteolytically inactivates the clotting factors Va and VIIIa, damping down coagulation; it modulates inflammation through signalling pathways such as protease-activated receptor 1; and it exerts cytoprotective effects that help endothelial barriers survive injury. Because these functions depend on precisely choreographed interactions with other plasma and cell-surface proteins, the activity of protein C cannot be inferred from its concentration alone. Its structural conformation, its binding partners and the surrounding protein context all shape what it actually does in the bloodstream. This distinction matters enormously in paediatrics, where reference ranges for clotting proteins differ dramatically from adult norms and where children are neither small adults nor scaled-down versions of them.

The Melbourne team set out to interrogate this hidden dimension using co-immunoprecipitation, a technique that exploits the specificity of an antibody to fish a target protein, and everything physically bound to it, out of a complex biological mixture. Working with plasma samples pooled into age groups spanning neonates to adults, the researchers used an anti-protein C antibody to capture protein C along with its interacting partners. The captured proteins were then digested and identified by liquid chromatography coupled to tandem mass spectrometry, or LC-MS/MS, the workhorse technology of modern proteomics. By comparing which proteins were enriched in the protein C pull-downs relative to controls, and which were depleted, the team could build an age-resolved picture of the protein C interactome. Multivariate tools including principal component analysis and partial least squares discriminant analysis were then applied to test whether the co-precipitating proteomes segregated cleanly by age, while functional enrichment analysis asked what biological pathways the changing partners represented.

The answer was emphatic. The protein C co-precipitating proteome changed substantially across development, and the differences were most pronounced in the youngest cohorts. In neonates and infants, the enrichment of protein C itself in the pull-downs was the most striking feature, hinting that the molecular environment surrounding protein C in early life differs fundamentally from that of later childhood and adulthood. The number of identifiable interaction partners also fluctuated in unexpected ways: the largest complement of protein C associates appeared in the 11 to 16 year-old group, while the smallest was found in children aged 6 to 10. That the peak of interaction complexity occurs in adolescence, rather than adulthood, was among the more surprising patterns to emerge from the data, suggesting that the adolescent haemostatic system may be assembling a particularly rich set of protein C-centred complexes as it transitions toward the mature adult state.

What kinds of proteins were keeping company with protein C? The functional analyses pointed to age-specific networks spanning several biological domains. Beyond the expected haemostatic partners, the co-precipitating proteins included platelet-related proteins, components of the complement cascade, and immune-related proteins. This breadth is biologically provocative. It implies that protein C does not operate in a closed coagulation circuit but sits at the intersection of clotting, innate immunity and inflammatory signalling, and that the relative weight of these connections shifts with age. In early development, when the immune system is still calibrating its responses and the vascular system is maturing, protein C may be drawn into different protein communities than in adulthood, when the networks have settled into their mature configuration. The plasma proteome, in other words, is not a fixed backdrop but a shifting stage on which protein C plays a changing role.

Yet the study also uncovered a deeper layer of conservation beneath the surface variability. When the researchers performed pathway analysis on the age-specific interactomes, they found significant cross-over in the biological pathways represented across age ranges, even though the individual proteins identified as participating in those pathways differed. The same functional themes, coagulation regulation, platelet biology, complement activation and immune modulation, recurred from neonates to adults, but with different molecular actors filling the roles at each stage. This is a conceptually important finding: it suggests that the developing haemostatic system maintains its core functions by swapping components rather than by inventing new ones. The orchestra keeps playing the same symphony, but the instrumentation changes with age, and protein C sits at the centre of the score.

The technical achievement underlying these conclusions should not be understated. Co-immunoprecipitation from plasma is notoriously challenging, because abundant proteins such as albumin and immunoglobulins can swamp the signal, and transient or weak interactions may not survive the capture process. The team’s workflow, incorporating filter-assisted sample preparation and rigorous false discovery rate control in the mass spectrometric identifications, was designed to separate genuine co-precipitating partners from background. Pooling samples within age groups provided the statistical power needed to detect developmental trends, though it also means the study captures population-level patterns rather than individual variation. The raw data have been deposited in the ProteomeXchange repository under identifier PXD077907, allowing other researchers to reanalyse the interactomes and test the team’s interpretations independently, a transparency measure that strengthens confidence in the findings.

The clinical implications reach into one of the persistent puzzles of paediatric medicine: why children’s clotting systems behave so differently from adults’, and why therapies calibrated on adult data can misfire in young patients. Developmental haemostasis, the recognition that the coagulation system matures in a coordinated but non-uniform fashion, has reshaped how paediatric haematologists interpret clotting tests and dose anticoagulants. This study adds a new dimension to that framework. If protein C’s interaction partners change with age, then the anticoagulant, anti-inflammatory and cytoprotective functions of the protein C pathway may likewise vary across development, even when measured concentrations appear adequate. For conditions in which protein C plays a documented role, from sepsis-associated coagulopathy to thrombotic risk in children, an age-aware interactome could eventually inform more precise diagnostic thresholds and treatment strategies. The work was funded through an Investigator Initiated Research Agreement with Takeda Pharmaceutical, which the authors state had no role in the design, analysis or decision to publish.

There remain, of course, important caveats and open questions. Co-immunoprecipitation identifies association, not necessarily direct binding, and some detected partners may reflect indirect membership of larger complexes. Pooled samples smooth over individual differences, and the functional consequences of most of the observed interactions remain to be tested experimentally. Whether the adolescent peak in interaction partners reflects a genuine biological programme or a transient compositional state of plasma will require longitudinal follow-up. Nevertheless, the study opens a genuinely new window onto developmental haemostasis. It demonstrates that the protein C interactome is a moving target, remodelling itself across childhood and adolescence, and that the functional identity of a well-characterised anticoagulant protein cannot be fully understood without accounting for the company it keeps. As proteomic techniques grow more sensitive, the shifting social network of protein C may prove to be a key to understanding why the blood of a newborn, a ten-year-old and an adult are three different molecular worlds.

Subject of Research: Age-dependent changes in the protein-protein interaction partners of protein C in human plasma across development

Article Title: Age-dependent changes in protein interaction partners of protein C

Article References: Age-dependent changes in protein interaction partners of protein C. (n.d.). https://doi.org/10.1186/s12014-026-09638-9

Image Credits: AI Generated

DOI: 10.1186/s12014-026-09638-9

Keywords: protein C, co-immunoprecipitation, LC-MS/MS, developmental haemostasis, interactome, protein-protein interactions, plasma proteome, paediatric haematology, coagulation, complement, mass spectrometry, proteomics

The human plasma proteome, the full collection of proteins measurable in the liquid portion of blood, sits at the intersection of genetics, metabolism and environment. Unlike DNA, which is essentially fixed from conception, the proteome responds dynamically to physiological states such as inflammation, insulin resistance, adipose tissue expansion and liver stress. Because many circulating proteins are secreted by adipose tissue or the liver and participate in cardiometabolic signaling, shifts in the plasma proteome are strong candidates for mediating the long-term consequences of childhood adiposity. Yet most previous studies captured only a single snapshot, typically in adulthood, leaving open the question of when in development these proteomic alterations first emerge and whether they are truly driven by fat mass or merely co-occur with it.

To address this, the research team analyzed plasma protein measurements at four timepoints across life, spanning childhood, adolescence and adulthood. Rather than relying on a single cohort or a single platform, the investigators combined multiple population-based birth cohorts in which participants had been followed from early life into adulthood, with blood samples collected, stored and later profiled using high-throughput affinity-based proteomic assays. These platforms, which measure thousands of unique proteins simultaneously using proximity extension assays or similar antibody-based technologies, allowed the researchers to quantify thousands of plasma proteins in the same individuals or closely matched cohorts at each life stage.

The central exposure was childhood adiposity, assessed through body mass index and other anthropometric indicators recorded during childhood and adolescence. The team then asked two complementary questions. First, is childhood adiposity associated with differences in plasma protein levels at the same timepoint, and does that association grow stronger as children age? Second, and more critically, does higher adiposity in childhood predict protein differences measured decades later, well after the original exposure, suggesting a durable biological imprint rather than a fleeting correlation?

The findings were striking. Higher childhood adiposity was associated with substantial proteomic differences detectable as early as childhood and adolescence, encompassing proteins involved in inflammation, leptin signaling, insulin action, extracellular matrix remodeling and lipoprotein metabolism. Among the most consistently affected proteins were well-established markers of cardiometabolic risk, including leptin, which scales tightly with fat mass, and inflammatory signaling molecules whose circulating levels are known to predict future cardiovascular events. The magnitude of these associations increased with age at measurement, indicating that the proteomic signature of excess adiposity intensifies as the metabolic consequences of obesity accumulate over time.

Importantly, many of the protein associations observed in childhood persisted into adulthood even after adjustment for adult body mass index. This persistence is a critical observation, because it suggests that childhood adiposity does more than simply track into adult overweight; it appears to leave a measurable molecular imprint on the circulating protein repertoire that is not fully explained by adult adiposity alone. In other words, a child who experienced excess body fat may carry a distinct proteomic profile decades later, even if they achieve a normal adult weight, pointing toward potential early-life biological embedding of cardiometabolic risk.

Associations alone cannot establish causation, and the researchers were careful to confront this limitation directly. Children with higher adiposity differ from their peers in diet, physical activity, socioeconomic circumstances and genetic liability, any of which could independently shape the proteome. To disentangle these possibilities, the study employed Mendelian randomization, a genetic epidemiological technique that uses naturally occurring genetic variants associated with adiposity as instrumental variables. Because genetic variants are randomly allocated at conception, they are largely immune to the confounding that plagues observational associations. When the team used genetic instruments for childhood body mass index to predict protein levels, they found that genetically influenced adiposity in childhood was linked to differences in many of the same proteins identified in the observational analyses, providing evidence consistent with a causal contribution of childhood fat mass to the plasma proteome.

The genetic analyses also illuminated which life stage matters most. By comparing the effects of genetic instruments for childhood adiposity with instruments for adult adiposity, the researchers could ask whether adult fat mass explains the protein associations or whether childhood-specific effects remain. For a subset of proteins, the childhood signal was independent of, and in some cases stronger than, the adult adiposity signal, supporting the idea that developmental windows exist during which excess adiposity exerts distinctive effects on circulating biology. This finding resonates with a broader literature showing that the timing of adiposity gain influences later disease risk more than body size at any single moment.

The study’s four-timepoint design also revealed trajectories. Some proteins showed associations that emerged in adolescence and strengthened through adulthood, consistent with cumulative metabolic injury. Others showed transient associations that attenuated with age, suggesting reversible responses to fat mass. A third group displayed persistent effects detectable decades after childhood, which the authors interpret as candidate mediators of the long-term disease burden attributable to early-life obesity. Proteins tied to inflammatory pathways, hepatic function and vascular biology featured prominently across these trajectories, aligning with the clinical observation that childhood obesity elevates risks of atherosclerosis, hypertension and metabolic liver disease well into midlife.

Technical rigor was a defining feature of the work. The investigators applied extensive quality control to the proteomic assays, adjusted for technical covariates such as batch effects and sample handling, and replicated key findings across independent cohorts and measurement platforms. Sensitivity analyses tested whether reverse causation, residual confounding or sample attrition could account for the results, and the consistency of protein associations across cohorts strengthened confidence in their robustness. The authors also acknowledged limitations, including the predominance of European-ancestry populations in available genetic reference data, the incomplete coverage of the proteome by current affinity-based platforms, and the possibility that some genetic instruments reflect correlated traits rather than adiposity itself.

The implications extend beyond observational epidemiology. Identifying which proteins are causally reshaped by childhood adiposity provides a starting point for understanding how early-life obesity is translated, at the molecular level, into adult disease. If specific circulating proteins prove to be genuine mediators, they could serve as early-warning biomarkers, allowing clinicians to identify children at elevated long-term risk before irreversible end-organ damage occurs. They could also expose therapeutic targets: drugs or interventions that normalize the proteomic consequences of excess adiposity during development might, in principle, interrupt the pathway from childhood obesity to adult cardiometabolic disease.

The work also contributes to an ongoing scientific debate about whether adult weight gain matters more or less than weight gained in childhood. Public health strategies have often focused on adult obesity, but accumulating evidence, including this proteomic analysis, suggests that adiposity during growth periods has biological consequences that are not simply undone by later weight normalization. The persistence of protein differences after accounting for adult body mass index argues for prevention efforts that begin in childhood, a message with significant relevance as childhood obesity rates continue to rise globally.

From a methodological standpoint, the study exemplifies a growing trend in life-course epidemiology: combining longitudinal cohorts, multiplexed proteomics and genetic causal inference to move from correlation toward mechanism. As proteomic platforms become cheaper and more comprehensive, and as large-scale genetic reference datasets expand across diverse ancestries, similar designs will be applied to other exposures, from early-life nutrition to environmental pollutants. The present findings establish childhood adiposity as a developmental exposure with quantifiable, durable and partly causal effects on the human plasma proteome, offering a molecular narrative for a clinical relationship that physicians have recognized for decades but could not previously explain at the protein level.

For researchers, the catalog of proteins altered by childhood adiposity represents a resource for mechanistic follow-up, including studies of adipose tissue biology, hepatic metabolism and vascular inflammation. For clinicians and policymakers, the results reinforce the urgency of early intervention. And for the thousands of cohort participants whose blood samples, collected decades ago in childhood, made the analysis possible, the work demonstrates the extraordinary scientific value of long-term longitudinal research in unraveling how the earliest chapters of biological life shape its later ones.

Subject of Research: Effects of childhood adiposity on the human plasma proteome across four lifecourse timepoints

Article Title: Evaluating the consequences of childhood adiposity on the human plasma proteome at four timepoints across the lifecourse

Article References: Dickson, P., Power, G. M., Niu, L., Holm, J.-C., Hansen, T., Turner, R. M., Gaunt, T. R., Davey Smith, G., & Richardson, T. G. (2026). Evaluating the consequences of childhood adiposity on the human plasma proteome at four timepoints across the lifecourse. Nature Communications. https://doi.org/10.1038/s41467-026-77097-9

Image Credits: AI Generated

DOI: 10.1038/s41467-026-77097-9

Keywords: childhood adiposity, plasma proteome, proteomics, Mendelian randomization, lifecourse epidemiology, obesity, cardiometabolic risk, inflammation, leptin, birth cohorts, protein biomarkers, Nature Communications